# NCT05208047 (NCT05208047)

> (Peak) A Phase 3 Randomized Trial of CGT9486+Sunitinib vs. Sunitinib in Subjects With Gastrointestinal Stromal Tumors

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05208047
- Phase: PHASE3
- Status: RECRUITING
- Sponsor: Cogent Biosciences, Inc.
- Conditions: Advanced Gastrointestinal Stromal Tumors; Metastatic Cancer
- Interventions: CGT9486; CGT9486; Sunitinib; Sunitinib; Midazolam; CGT9486; Sunitinib; CGT9486; Sunitinib
- Enrollment: 482
- Primary outcome: Part 1a - pharmacokinetics - Cmax
- Primary outcome: Part 1a - pharmacokinetics - AUC
- Primary outcome: Part 1b - pharmacokinetics - Cmax
- Primary outcome: Part 1b - pharmacokinetics - AUC
- Primary outcome: Part 1b - pharmacokinetics - Tmax
- Primary outcome: Part 2 - Progression Free Survival (PFS)
- Primary outcome: DDI Substudy - pharmacokinetics - AUC
- Primary outcome: DDI Substudy - pharmacokinetics - Cmax

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 3

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=nct05208047